EUVIMEDEUVIMED entdecken
Crossref

Synthesis of Immunoproteasome N‐Degron Prodrugs for Selective Protein Degradation

Cody A Loy iD, Timothy J Harris iD, Darci J Trader iD

Current Protocols · 2025

DOI: 10.1002/cpz1.70278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Protocols, 2025. Verfasst von Cody A Loy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Science, University of California, Irvine, California. Hauptthemen laut MEDLINE: Proteasome Endopeptidase Complex, Proteolysis, Prodrugs. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation using bifunctional molecules like proteolysis targeting chimeras (PROTACs) has revolutionized drug discovery but remains limited by E3 ligase availability and lack of cell selectivity. N‐degron degraders provide a smaller, more drug‐like alternative that harnesses endogenous N‐terminal degradation signals independent of recruited ligases. However, they are prone to proteolysis and lack mechanisms for tissue‐specific activation. To overcome these challenges, we developed a “caged” N‐degron degrader selectively activated by the immunoproteasome (iCP), a proteasome isoform induced in cancer and inflammatory settings. By appending an iCP‐recognition tetrapeptide (Ala‐Thr‐Met‐Trp) capped with a morpholine group to the N‐terminus, we shielded the degron from nonspecific cleavage and enabled selective activation in iCP‐expressing cells. This design improved stability, enhanced degradation potency, and minimized activity in healthy cells. Our findings establish a generalizable strategy to spatially control N‐degron activity through disease‐specific proteolytic environments, advancing safer and more selective protein degradation therapeutics. © 2025 Wiley Periodicals LLC. Basic Protocol 1 : Synthesis and characterization of an N‐degron degrader for Abl Basic Protocol 2 : Synthesis and characterization of an immunoproteasome N‐degron prodrug Basic Protocol 3 : Assessing protein degradation in cells

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome Endopeptidase ComplexProteolysisProdrugsHumansDegrons

Stichwörter der Autor:innen

N‐degronimmunoproteasomeprodrugproteostasistargeted protein degradation

Substanzen

Proteasome Endopeptidase ComplexProdrugs

Autor:innen und Institutionen

  • Department of Pharmaceutical Science, University of California, Irvine, California.
  • These authors contributed equally to this work.
  • Department of Chemistry, University of California, Irvine, California.
  • Robert A. Mah Molecular Innovation Center, University of California, Irvine, California.

ORCID-Profile: Cody A Loy, Timothy J Harris, Darci J Trader

Zitieren

APA

Loy, C. A., Harris, T. J., & Trader, D. J. (2025). Synthesis of Immunoproteasome N‐Degron Prodrugs for Selective Protein Degradation. Current Protocols. https://doi.org/10.1002/cpz1.70278

Vancouver

Loy CA, Harris TJ, Trader DJ. Synthesis of Immunoproteasome N‐Degron Prodrugs for Selective Protein Degradation. Current Protocols. 2025. doi:10.1002/cpz1.70278

BibTeX
@article{Loy2025,
  author = {Loy, Cody A and Harris, Timothy J and Trader, Darci J},
  title = {Synthesis of Immunoproteasome N‐Degron Prodrugs for Selective Protein Degradation},
  journal = {Current Protocols},
  year = {2025},
  doi = {10.1002/cpz1.70278}
}
Kostenlos starten →